A holistic review of recent advances in nano-based drug delivery systems for the treatment of triple-negative breast cancer (TNBC)
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Martin C, Aibani N, Callan JF, Callan B (2016) Recent advances in amphiphilic polymers for simultaneous delivery of hydrophobic and hydrophilic drugs. Ther. Deliv 7(1):15–31. https://doi.org/10.4155/tde.15.8410.4155/tde.15.84 ↗
2. Guan L, Rizzello L, Battaglia G (2015) Polymersomes and their applications in cancer delivery and therapy. Nanomedicine 10(17):2757–2780. https://doi.org/10.2217/nnm.15.11010.2217/nnm.15.110 ↗
3. Karandish F et al (2018) Nucleus-Targeted, Echogenic Polymersomes for Delivering a Cancer Stemness Inhibitor to Pancreatic Cancer Cells. Biomacromolecules 19(10):4122–4132. https://doi.org/10.1021/acs.biomac.8b0113310.1021/acs.biomac.8b01133 ↗
4. Golombek SK et al (2018) Tumor targeting via EPR: Strategies to enhance patient responses. Adv Drug Deliv Rev 130:17–38. https://doi.org/10.1016/j.addr.2018.07.00710.1016/j.addr.2018.07.007 ↗
5. MacDonald I, Nixon NA, Khan OF (2022) Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies. Curr Oncol 29(7):4768–4778. https://doi.org/10.3390/curroncol2907037810.3390/curroncol29070378 ↗
6. Kesharwani P, Sheikh A, Abourehab MAS, Salve R, Gajbhiye V (2023) A combinatorial delivery of survivin targeted siRNA using cancer selective nanoparticles for triple negative breast cancer therapy. J Drug Deliv Sci Technol 80:104164. https://doi.org/10.1016/j.jddst.2023.10416410.1016/j.jddst.2023.104164 ↗
7. Kulkarni P, Haldar MK, You S, Choi Y, Mallik S (2016) Hypoxia-Responsive Polymersomes for Drug Delivery to Hypoxic Pancreatic Cancer Cells. Biomacromolecules 17(8):2507–2513. https://doi.org/10.1021/acs.biomac.6b0035010.1021/acs.biomac.6b00350 ↗
8. Confeld MI et al (2020) Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors. Mol Pharm 17(8):2849–2863. https://doi.org/10.1021/acs.molpharmaceut.0c0024710.1021/acs.molpharmaceut.0c00247 ↗
9. Deng ZJ, Morton SW, Ben-Akiva E, Dreaden EC, Shopsowitz KE, Hammond PT (2013) Layer-by-Layer Nanoparticles for Systemic Codelivery of an Anticancer Drug and siRNA for Potential Triple-Negative Breast Cancer Treatment. ACS Nano 7(11):9571–9584. https://doi.org/10.1021/nn404792510.1021/nn4047925 ↗
10. Zhang Y et al (2017) Tumor-Targeting Micelles Based on Linear-Dendritic PEG–PTX 8 Conjugate for Triple Negative Breast Cancer Therapy. Mol Pharm 14(10):3409–3421. https://doi.org/10.1021/acs.molpharmaceut.7b0043010.1021/acs.molpharmaceut.7b00430 ↗
11. Brinkman AM et al (2016) Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer. Biomaterials 101:20–31. https://doi.org/10.1016/j.biomaterials.2016.05.04110.1016/j.biomaterials.2016.05.041 ↗
12. Torres-Pérez SA, del P Ramos-Godínez M, Ramón-Gallegos E (2019) Effect of methotrexate conjugated PAMAM dendrimers on the viability of breast cancer cells. p 050014. https://doi.org/10.1063/1.509592910.1063/1.5095929 ↗
13. Wu X, Han Z, Schur RM, Lu Z-R (2016) Targeted Mesoporous Silica Nanoparticles Delivering Arsenic Trioxide with Environment Sensitive Drug Release for Effective Treatment of Triple Negative Breast Cancer. ACS Biomater Sci Eng 2(4):501–507. https://doi.org/10.1021/acsbiomaterials.5b0039810.1021/acsbiomaterials.5b00398 ↗
14. Lü L et al (2017) MicroRNAs in the prognosis of triple-negative breast cancer. Medicine (Baltimore) 96(22):e7085. https://doi.org/10.1097/MD.000000000000708510.1097/MD.0000000000007085 ↗
15. Zhu H, Dai M, Chen X, Chen X, Qin S, Dai S (2017) Integrated analysis of the potential roles of miRNA-mRNA networks in triple negative breast cancer. Mol Med Rep 16(2):1139–1146. https://doi.org/10.3892/mmr.2017.675010.3892/mmr.2017.6750 ↗
16. Rastogi P et al (2008) Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26(5):778–785. https://doi.org/10.1200/JCO.2007.15.023510.1200/JCO.2007.15.0235 ↗
17. Zhao L, Gu C, Gan Y, Shao L, Chen H, Zhu H (2020) Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis. J Control Release 318:1–15. https://doi.org/10.1016/j.jconrel.2019.12.00510.1016/j.jconrel.2019.12.005 ↗
18. Guo P, You J-O, Yang J, Jia D, Moses MA, Auguste DT (2014) Inhibiting Metastatic Breast Cancer Cell Migration via the Synergy of Targeted, pH-triggered siRNA Delivery and Chemokine Axis Blockade. Mol Pharm. 11(3):755–765. https://doi.org/10.1021/mp400469910.1021/mp4004699 ↗
19. Lee E et al (2020) Glutathione peroxidase-1 regulates adhesion and metastasis of triple-negative breast cancer cells via FAK signaling. Redox Biol 29:101391. https://doi.org/10.1016/j.redox.2019.10139110.1016/j.redox.2019.101391 ↗
20. Zhang Y et al (2020) Non-SMC Condensin I Complex Subunit D2 Is a Prognostic Factor in Triple-Negative Breast Cancer for the Ability to Promote Cell Cycle and Enhance Invasion. Am J Pathol. 190(1):37–47. https://doi.org/10.1016/j.ajpath.2019.09.01410.1016/j.ajpath.2019.09.014 ↗
21. Medina MA et al (2020) Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. Int J Environ Res Public Health 17(6):2078. https://doi.org/10.3390/ijerph1706207810.3390/ijerph17062078 ↗
22. Dana H et al (2017) Molecular Mechanisms and Biological Functions of siRNA. IJBS 1310.59566/IJBS.2017.13048 ↗
23. Macias H, Hinck L (2012) Mammary gland development. Wiley Interdiscip Rev Dev Biol 1(4):533–557. https://doi.org/10.1002/wdev.3510.1002/wdev.35 ↗
24. Huebner RJ, Ewald AJ (2014) Cellular foundations of mammary tubulogenesis. Semin Cell Dev Biol 31:124–131. https://doi.org/10.1016/j.semcdb.2014.04.01910.1016/j.semcdb.2014.04.019 ↗
25. Hunter T (2000) Signaling—2000 and Beyond. Cell 100(1):113–127. https://doi.org/10.1016/S0092-8674(00)81688-810.1016/S0092-8674(00)81688-8 ↗
26. Hunter T (2007) The Age of Crosstalk: Phosphorylation, Ubiquitination, and Beyond. Mol Cell 28(5):730–738. https://doi.org/10.1016/j.molcel.2007.11.01910.1016/j.molcel.2007.11.019 ↗
27. Sever R, Brugge JS (2015) Signal Transduction in Cancer. Cold Spring Harb Perspect Med 5(4):a006098–a006098. https://doi.org/10.1101/cshperspect.a00609810.1101/cshperspect.a006098 ↗
28. Kumar V, Green S, Stack G, Berry M, Jin J-R, Chambon P (1987) Functional domains of the human estrogen receptor. Cell 51(6):941–951. https://doi.org/10.1016/0092-8674(87)90581-210.1016/0092-8674(87)90581-2 ↗
29. Kent Osborne C, Schiff R, Fuqua SAW, Shou J (2001). Estrogen Receptor: Current Understanding of Its Activation and Modulation. Clin Cancer Res 7
30. Renoir J-M, Marsaud V, Lazennec G (2013) Estrogen receptor signaling as a target for novel breast cancer therapeutics. Biochem Pharmacol 85(4):449–465. https://doi.org/10.1016/j.bcp.2012.10.01810.1016/j.bcp.2012.10.018 ↗
31. Cheskis BJ, Greger JG, Nagpal S, Freedman LP (2007) Signaling by estrogens. J Cell Physiol 213(3):610–617. https://doi.org/10.1002/jcp.2125310.1002/jcp.21253 ↗
32. Björnström L, Sjöberg M (2005) Mechanisms of Estrogen Receptor Signaling: Convergence of Genomic and Nongenomic Actions on Target Genes. Mol Endocrinol 19(4):833–842. https://doi.org/10.1210/me.2004-048610.1210/me.2004-0486 ↗
33. Saha Roy S, Vadlamudi RK (2012) Role of Estrogen Receptor Signaling in Breast Cancer Metastasis. Int J Breast Cancer 2012:1–8. https://doi.org/10.1155/2012/65469810.1155/2012/654698 ↗
34. Klinge CM (2000) Estrogen receptor interaction with co-activators and co-repressors☆. Steroids 65(5):227–251. https://doi.org/10.1016/S0039-128X(99)00107-510.1016/S0039-128X(99)00107-5 ↗
35. Marino M, Galluzzo P, Ascenzi P (2006) Estrogen Signaling Multiple Pathways to Impact Gene Transcription. Curr Genomics 7(8):497–508. https://doi.org/10.2174/13892020677931573710.2174/138920206779315737 ↗
36. Fan S et al (1999) BRCA1 Inhibition of Estrogen Receptor Signaling in Transfected Cells. Science (80-) 284(5418):1354–1356 https://doi.org/10.1126/science.284.5418.1354.10.1126/science.284.5418.1354 ↗
37. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR (2005) Immunohistochemistry of Estrogen and Progesterone Receptors Reconsidered. Am J Clin Pathol 123(1):21–27. https://doi.org/10.1309/4WV79N2GHJ3X184110.1309/4WV79N2GHJ3X1841 ↗
38. Medina MA, Oza G, Sharma A, Arriaga LG, Hernández Hernández JM, Rotello VM, Ramirez JT (2020) Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. https://doi.org/10.3390/ijerph17062078.10.3390/ijerph17062078 ↗
39. Shokooh MK, Emami F, Jeong J-H, Yook S Bio-Inspired and Smart Nanoparticles for Triple Negative Breast Cancer Microenvironment. Pharmaceutics 13:287. https://doi.org/10.3390/pharmaceutics1302028710.3390/pharmaceutics13020287 ↗
40. Silva-Cázares MB, Saavedra-Leos MZ, Jordan-Alejandre E, Nuñez-Olvera S, Cómpean-Martínez I, López-Camarillo C (2020) Lipid-based nanoparticles for the therapeutic delivery of non-coding RNAs in breast cancer (Review). Oncol Rep 44:2353-2363 https://doi.org/10.3892/or.2020.779110.3892/or.2020.7791 ↗
41. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC (2014) Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 66:2–25. https://doi.org/10.1016/j.addr.2013.11.00910.1016/j.addr.2013.11.009 ↗
42. Miller-Kleinhenz JM, Bozeman EN, Yang L (2015) Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances. Wiley Interdiscip Rev Nanomedicine Nanobiotechnology 7(6):797–816. https://doi.org/10.1002/wnan.134310.1002/wnan.1343 ↗
43. Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues. JNCI J Natl Cancer Inst 94(4):252–266. https://doi.org/10.1093/jnci/94.4.25210.1093/jnci/94.4.252 ↗
44. Ramirez LY, Huestis SE, Yap TY, Zyzanski S, Drotar D, Kodish E (2009) Potential chemotherapy side effects: What do oncologists tell parents? Pediatr Blood Cancer 52(4):497–502. https://doi.org/10.1002/pbc.2183510.1002/pbc.21835 ↗
45. Bagnyukova TV, Serebriiskii IG, Zhou Y, Hopper-Borge EA, Golemis EA, Astsaturov I (2010) Chemotherapy and signaling. Cancer Biol Ther 10(9):839–853. https://doi.org/10.4161/cbt.10.9.1373810.4161/cbt.10.9.13738 ↗
46. Hu D et al (2018) Oxygen-generating Hybrid Polymeric Nanoparticles with Encapsulated Doxorubicin and Chlorin e6 for Trimodal Imaging-Guided Combined Chemo-Photodynamic Therapy. Theranostics 8(6):1558–1574. https://doi.org/10.7150/thno.2298910.7150/thno.22989 ↗
47. Yuan J-D et al (2018) pH-sensitive polymeric nanoparticles of mPEG-PLGA-PGlu with hybrid core for simultaneous encapsulation of curcumin and doxorubicin to kill the heterogeneous tumour cells in breast cancer. Artif Cells, Nanomedicine, Biotechnol 46(sup1):302–313. https://doi.org/10.1080/21691401.2017.142349510.1080/21691401.2017.1423495 ↗
48. Khanna V, Kalscheuer S, Kirtane A, Zhang W, Panyam J (2019) Perlecan-targeted nanoparticles for drug delivery to triple-negative breast cancer. Futur Drug Discov 1(1) https://doi.org/10.4155/fdd-2019-000510.4155/fdd-2019-0005 ↗
49. Zhang R et al (2019) Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer. Small 15(49):1903881. https://doi.org/10.1002/smll.20190388110.1002/smll.201903881 ↗
50. Wang S et al (2017) Co-delivery of gambogic acid and TRAIL plasmid by hyaluronic acid grafted PEI-PLGA nanoparticles for the treatment of triple negative breast cancer. Drug Deliv 24(1):1791–1800. https://doi.org/10.1080/10717544.2017.140655810.1080/10717544.2017.1406558 ↗
51. Duan X, Chan C, Guo N, Han W, Weichselbaum RR, Lin W (2016) Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer. J Am Chem Soc 138(51):16686–16695. https://doi.org/10.1021/jacs.6b0953810.1021/jacs.6b09538 ↗
52. Martin JD, Cabral H, Stylianopoulos T, Jain RK (2020) Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat Rev Clin Oncol 17(4):251–266. https://doi.org/10.1038/s41571-019-0308-z10.1038/s41571-019-0308-z ↗
53. Goldberg MS (2019) Improving cancer immunotherapy through nanotechnology. Nat Rev Cancer 19(10):587–602. https://doi.org/10.1038/s41568-019-0186-910.1038/s41568-019-0186-9 ↗
54. Schmid P et al (2018) Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 379(22):2108–2121. https://doi.org/10.1056/NEJMoa180961510.1056/NEJMoa1809615 ↗
55. Thambi T et al (2014) Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery. Biomaterials 35(5):1735–1743. https://doi.org/10.1016/j.biomaterials.2013.11.02210.1016/j.biomaterials.2013.11.022 ↗
56. Esfandiari N, Arzanani MK, Soleimani M, Kohi-Habibi M, Svendsen WE (2016) A new application of plant virus nanoparticles as drug delivery in breast cancer. Tumor Biol 37(1):1229–1236. https://doi.org/10.1007/s13277-015-3867-310.1007/s13277-015-3867-3 ↗
57. Le DHT, Lee KL, Shukla S, Commandeur U, Steinmetz NF (2017) Potato virus X, a filamentous plant viral nanoparticle for doxorubicin delivery in cancer therapy. Nanoscale 9(6):2348–2357. https://doi.org/10.1039/C6NR09099K10.1039/C6NR09099K ↗
58. Wahajuddin and Arora (2012) Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int J Nanomedicine 3445. https://doi.org/10.2147/IJN.S3032010.2147/IJN.S30320 ↗
59. Neuberger T, Schöpf B, Hofmann H, Hofmann M, von Rechenberg B (2005) Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system. J Magn Magn Mater 293(1):483–496. https://doi.org/10.1016/j.jmmm.2005.01.06410.1016/j.jmmm.2005.01.064 ↗
60. Trivino A, Gumireddy A, Chauhan H (2019) Drug-Lipid-Surfactant Miscibility for the Development of Solid Lipid Nanoparticles. AAPS PharmSciTech 20(2):46. https://doi.org/10.1208/s12249-018-1229-310.1208/s12249-018-1229-3 ↗
61. Meng H et al (2013) Codelivery of an Optimal Drug/siRNA Combination Using Mesoporous Silica Nanoparticles To Overcome Drug Resistance in Breast Cancer in Vitro and in Vivo. ACS Nano 7(2):994–1005. https://doi.org/10.1021/nn304406610.1021/nn3044066 ↗
62. Yong K-T et al (2007) Quantum Rod Bioconjugates as Targeted Probes for Confocal and Two-Photon Fluorescence Imaging of Cancer Cells. Nano Lett 7(3):761–765. https://doi.org/10.1021/nl063031m10.1021/nl063031m ↗
63. Loo C, Lowery A, Halas N, West J, Drezek R (2005) Immunotargeted Nanoshells for Integrated Cancer Imaging and Therapy. Nano Lett 5(4):709–711. https://doi.org/10.1021/nl050127s10.1021/nl050127s ↗
64. Hirsch LR et al (2003) Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci 100(23):13549–13554. https://doi.org/10.1073/pnas.223247910010.1073/pnas.2232479100 ↗
65. Pan B et al (2007) Dendrimer-Modified Magnetic Nanoparticles Enhance Efficiency of Gene Delivery System. Cancer Res. 67(17):8156–8163. https://doi.org/10.1158/0008-5472.CAN-06-476210.1158/0008-5472.CAN-06-4762 ↗
66. Cloninger MJ (2002) Biological applications of dendrimers. Curr Opin Chem Biol 6(6):742–748. https://doi.org/10.1016/S1367-5931(02)00400-310.1016/S1367-5931(02)00400-3 ↗
67. Toh T-B et al (2014) Nanodiamond–Mitoxantrone Complexes Enhance Drug Retention in Chemoresistant Breast Cancer Cells. Mol Pharm 11(8):2683–2691. https://doi.org/10.1021/mp500110810.1021/mp5001108 ↗
68. Zhang P et al (2016) Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial. Oncotarget 7(37):60647–60656 https://doi.org/10.18632/oncotarget.10607.10.18632/oncotarget.10607 ↗
69. Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T (2018) Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res 8(5):1483–1507. https://doi.org/10.1007/s13346-018-0551-310.1007/s13346-018-0551-3 ↗
70. Piccart-Gebhart MJ et al (2005) Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl J Med 353(16):1659–1672. https://doi.org/10.1056/NEJMoa05230610.1056/NEJMoa052306 ↗
71. Waks AG, Winer EP (2019) Breast Cancer Treatment. JAMA 321(3):288. https://doi.org/10.1001/jama.2018.1932310.1001/jama.2018.19323 ↗
72. Lim E, Palmieri C, Tilley WD (2016) Renewed interest in the progesterone receptor in breast cancer. Br J Cancer 115(8):909–911. https://doi.org/10.1038/bjc.2016.30310.1038/bjc.2016.303 ↗
73. Joshi H, Press MF (2018) Molecular Oncology of Breast Cancer. In: The Breast, Elsevier, pp. 282-307.e5. https://doi.org/10.1016/B978-0-323-35955-9.00022-210.1016/B978-0-323-35955-9.00022-2 ↗
74. Al-Warhi T, Sabt A, Elkaeed EB, Eldehna WM (2020) Recent advancements of coumarin-based anticancer agents: An up-to-date review. Bioorg Chem 103:104163. https://doi.org/10.1016/j.bioorg.2020.10416310.1016/j.bioorg.2020.104163 ↗
75. Bae YH, Park K (2011) Targeted drug delivery to tumors: Myths, reality and possibility. J Control Release 153(3):198–205. https://doi.org/10.1016/j.jconrel.2011.06.00110.1016/j.jconrel.2011.06.001 ↗
76. Zhang L, Gu F, Chan J, Wang A, Langer R, Farokhzad O (2008) Nanoparticles in Medicine: Therapeutic Applications and Developments. Clin Pharmacol Ther 83(5):761–769. https://doi.org/10.1038/sj.clpt.610040010.1038/sj.clpt.6100400 ↗
77. Hirsjarvi S, Passirani C, Benoit J-P (2011) Passive and Active Tumour Targeting with Nanocarriers. Curr Drug Discov Technol 8(3):188–196. https://doi.org/10.2174/15701631179679899110.2174/157016311796798991 ↗
78. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol10.1038/nnano.2007.387 ↗
79. Mostafavi Yazdi SJ, Cho S, Lee J-H (2021) Analysis and optimization of six types of two-coil inductive for the human implantable wireless electrocardiogram sensor. In: Optical Fibers and Sensors for Medical Diagnostics. Treatment and Environ Appl XXI, p 12. https://doi.org/10.1117/12.258237210.1117/12.2582372 ↗
80. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016) Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13(11):674–690. https://doi.org/10.1038/nrclinonc.2016.6610.1038/nrclinonc.2016.66 ↗
81. Bosch A, Eroles P, Zaragoza R, Viña JR, Lluch A (2010) Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 36(3):206–215. https://doi.org/10.1016/j.ctrv.2009.12.00210.1016/j.ctrv.2009.12.002 ↗
82. Murugan C et al (2016) Combinatorial nanocarrier based drug delivery approach for amalgamation of anti-tumor agents in breast cancer cells: an improved nanomedicine strategy. Sci Rep 6(1):34053. https://doi.org/10.1038/srep3405310.1038/srep34053 ↗
83. Pawar A, Prabhu P (2019) Nanosoldiers: A promising strategy to combat triple negative breast cancer. Biomed Pharmacother 110:319–341. https://doi.org/10.1016/j.biopha.2018.11.12210.1016/j.biopha.2018.11.122 ↗
84. Abdulkarim BS, Cuartero J, Hanson J, Deschênes J, Lesniak D, Sabri S (2011) Increased Risk of Locoregional Recurrence for Women With T1–2N0 Triple-Negative Breast Cancer Treated With Modified Radical Mastectomy Without Adjuvant Radiation Therapy Compared With Breast-Conserving Therapy. J Clin Oncol. 29(21):2852–2858. https://doi.org/10.1200/JCO.2010.33.471410.1200/JCO.2010.33.4714 ↗
85. von Minckwitz G et al (2010) Abstract S4-6: Neoadjuvant Chemotherapy with or without Bevacizumab: Primary Efficacy Endpoint Analysis of the GEPARQUINTO Study (GBG 44). Cancer Res 70(24_Supplement): S4-6 https://doi.org/10.1158/0008-5472.SABCS10-S4-610.1158/0008-5472.SABCS10-S4-6 ↗
86. Gerber B et al (2013) Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol 24(12):2978–2984. https://doi.org/10.1093/annonc/mdt36110.1093/annonc/mdt361 ↗
87. Gennari A et al (2008) HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials. JNCI J Natl Cancer Inst 100(1):14–20. https://doi.org/10.1093/jnci/djm25210.1093/jnci/djm252 ↗
88. Slamon D, Mackey J, Robert N, Crown J, Martin M, Eiremann W et al (2007) Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease. Springer
89. von Minckwitz G et al (2012) Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. J Clin Oncol 30(15):1796–1804. https://doi.org/10.1200/JCO.2011.38.859510.1200/JCO.2011.38.8595 ↗
90. Cortazar P et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164–172. https://doi.org/10.1016/S0140-6736(13)62422-810.1016/S0140-6736(13)62422-8 ↗
91. Asselain B et al (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 19(1):27–39. https://doi.org/10.1016/S1470-2045(17)30777-510.1016/S1470-2045(17)30777-5 ↗
92. Maughan KL, Lutterbie MA, Ham PS (2010) Treatment of breast cancer. Natl Libr Med
93. Moo T-A, Sanford R, Dang C, Morrow M (2018) Overview of Breast Cancer Therapy. PET Clin 13(3):339–354. https://doi.org/10.1016/j.cpet.2018.02.00610.1016/j.cpet.2018.02.006 ↗
94. Fosu-Mensah N, Peris MS, Weeks HP, Cai J, Westwell AD (2015) Advances in small-molecule drug discovery for triple-negative breast cancer. Future Med Chem 7(15):2019–2039. https://doi.org/10.4155/fmc.15.12910.4155/fmc.15.129 ↗
95. Kalimutho M, Parsons K, Mittal D, López JA, Srihari S, Khanna KK (2015) Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. Trends Pharmacol Sci 36(12):822–846. https://doi.org/10.1016/j.tips.2015.08.00910.1016/j.tips.2015.08.009 ↗
96. Vaz-Luis I et al (2014) Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study. J Clin Oncol 32(20):2142–2150. https://doi.org/10.1200/JCO.2013.53.160810.1200/JCO.2013.53.1608 ↗
97. Metzger-Filho O et al (2012) Dissecting the Heterogeneity of Triple-Negative Breast Cancer. J Clin Oncol 30(15):1879–1887. https://doi.org/10.1200/JCO.2011.38.201010.1200/JCO.2011.38.2010 ↗
98. Lehmann BD et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750–2767. https://doi.org/10.1172/JCI4501410.1172/JCI45014 ↗
99. Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol. 8(3):235–244. https://doi.org/10.1016/S1470-2045(07)70074-810.1016/S1470-2045(07)70074-8 ↗
100. Mitra S (2017) MicroRNA Therapeutics in Triple Negative Breast Cancer. Arch Pathol Clin Res 1(1):009–017. https://doi.org/10.29328/journal.hjpcr.100100310.29328/journal.hjpcr.1001003 ↗